ADC 3680B

Drug Profile

ADC 3680B

Alternative Names: ADC3680; ADC3680B; PTR-36

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Pulmagen Therapeutics; Teijin
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Jul 2015 Phase-II development is ongoing for Asthma in USA and Europe
  • 07 Dec 2014 Pulmagen Therapeutics completes a phase II trial in Asthma in USA, Croatia, Czech Republic, Germany, Hungary and Poland (NCT01730027)
  • 11 Nov 2013 Phase-II clinical trials in Asthma in Croatia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top